Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   37528   clinical trials with a EudraCT protocol, of which   6154   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-659 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis

    Summary
    EudraCT number
    2016-003585-11
    Trial protocol
    IE   GB  
    Global end of trial date
    28 Feb 2018

    Results information
    Results version number
    v1(current)
    This version publication date
    16 Mar 2019
    First version publication date
    16 Mar 2019
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    VX16-659-101
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT03224351
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Vertex Pharmaceuticals Incorporated
    Sponsor organisation address
    50 Northern Avenue, Boston, Massachusetts, United States,
    Public contact
    Medical Monitor, Vertex Pharmaceuticals Incorporated, +1 877 634 8789, medicalinfo@vrtx.com
    Scientific contact
    Medical Monitor, Vertex Pharmaceuticals Incorporated, +1 877 634 8789, medicalinfo@vrtx.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    28 Mar 2018
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    28 Feb 2018
    Global end of trial reached?
    Yes
    Global end of trial date
    28 Feb 2018
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To evaluate the safety, tolerability, and efficacy of VX-659 in triple combination (TC) with Tezacaftor/Ivacaftor (TEZ/IVA) or with TEZ/VX-561.
    Protection of trial subjects
    The study was conducted in accordance with the ethical principles stated in the Declaration of Helsinki and the International Council on Harmonization (ICH) Guideline for Good Clinical Practice (GCP).
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    08 Aug 2017
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    United Kingdom: 29
    Country: Number of subjects enrolled
    Ireland: 11
    Country: Number of subjects enrolled
    United States: 77
    Country: Number of subjects enrolled
    Israel: 7
    Worldwide total number of subjects
    124
    EEA total number of subjects
    40
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    124
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    This study included 3 parts and was conducted in adult subjects with cystic fibrosis (CF).

    Period 1
    Period 1 title
    Triple Combination Treatment Period (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Assessor

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Part 1: Placebo
    Arm description
    Subjects received placebo matched to VX-659/TEZ/IVA triple combination (TC) for 4 weeks in the TC treatment period.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo (matched to VX-659)
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received placebo matched to VX-659 once daily.

    Investigational medicinal product name
    Placebo (matched to TEZ/IVA)
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received placebo matched to TEZ/IVA once daily in the morning.

    Investigational medicinal product name
    Placebo (matched to IVA)
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received placebo matched to IVA once daily in the evening.

    Arm title
    Part 1: VX-659/TEZ/IVA TC - Low Dose
    Arm description
    Subjects received VX-659/TEZ/IVA TC low dose for 4 weeks in the TC treatment period.
    Arm type
    Experimental

    Investigational medicinal product name
    VX-659
    Investigational medicinal product code
    VX-659
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received VX-659 low dose once daily.

    Investigational medicinal product name
    TEZ/IVA
    Investigational medicinal product code
    VX-661/VX-770
    Other name
    Tezacaftor/Ivacaftor fixed dose combination
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received TEZ/IVA once daily in the morning.

    Investigational medicinal product name
    IVA
    Investigational medicinal product code
    VX-770
    Other name
    Ivacaftor
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received IVA once daily in the evening.

    Arm title
    Part 1: VX-659/TEZ/IVA TC - Medium Dose
    Arm description
    Subjects received VX-659/TEZ/IVA TC medium dose for 4 weeks in the TC treatment period.
    Arm type
    Experimental

    Investigational medicinal product name
    VX-659
    Investigational medicinal product code
    VX-659
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received VX-659 medium dose once daily.

    Investigational medicinal product name
    TEZ/IVA
    Investigational medicinal product code
    VX-661/VX-770
    Other name
    Tezacaftor/Ivacaftor fixed dose combination
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received TEZ/IVA once daily in the morning.

    Investigational medicinal product name
    IVA
    Investigational medicinal product code
    VX-770
    Other name
    Ivacaftor
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received IVA once daily in the evening.

    Arm title
    Part 1: VX-659/TEZ/IVA TC - High Dose
    Arm description
    Subjects received VX-659/TEZ/IVA TC high dose for 4 weeks in the TC treatment period.
    Arm type
    Experimental

    Investigational medicinal product name
    VX-659
    Investigational medicinal product code
    VX-659
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received VX-659 high dose once daily.

    Investigational medicinal product name
    TEZ/IVA
    Investigational medicinal product code
    VX-661/VX-770
    Other name
    Tezacaftor/Ivacaftor fixed dose combination
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received TEZ/IVA once daily in the morning.

    Investigational medicinal product name
    IVA
    Investigational medicinal product code
    VX-770
    Other name
    Ivacaftor
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received IVA once daily in the evening.

    Arm title
    Part 2: TEZ/IVA
    Arm description
    Following run-in period of 4 weeks with TEZ/IVA, subjects received TEZ/IVA and placebo matched to VX-659 for 4 weeks in the TC treatment period.
    Arm type
    Active comparator

    Investigational medicinal product name
    Placebo (matched to VX-659)
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received placebo matched to VX-659 once daily.

    Investigational medicinal product name
    TEZ/IVA
    Investigational medicinal product code
    VX-661/VX-770
    Other name
    Tezacaftor/Ivacaftor fixed dose combination
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received TEZ/IVA once daily in the morning.

    Investigational medicinal product name
    IVA
    Investigational medicinal product code
    VX-770
    Other name
    Ivacaftor
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received IVA once daily in the evening.

    Arm title
    Part 2: VX-659/TEZ/IVA TC
    Arm description
    Following run-in period of 4 weeks with TEZ/IVA, subjects received VX-659/TEZ/IVA for 4 weeks in the TC treatment period.
    Arm type
    Experimental

    Investigational medicinal product name
    VX-659
    Investigational medicinal product code
    VX-659
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received VX-659 once daily.

    Investigational medicinal product name
    TEZ/IVA
    Investigational medicinal product code
    VX-661/VX-770
    Other name
    Tezacaftor/Ivacaftor fixed dose combination
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received TEZ/IVA once daily in the morning.

    Investigational medicinal product name
    IVA
    Investigational medicinal product code
    VX-770
    Other name
    Ivacaftor
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received IVA once daily in the evening.

    Arm title
    Part 3: Placebo
    Arm description
    Subjects received placebo matched to VX-659/TEZ/VX-561 TC for 4 weeks in the TC treatment period.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo (matched to VX-659)
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received placebo matched to VX-659 once daily.

    Investigational medicinal product name
    Placebo (matched to TEZ)
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received placebo matched to TEZ once daily.

    Investigational medicinal product name
    Placebo (matched to VX-561)
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received placebo matched to VX-561 once daily.

    Arm title
    Part 3: VX-659/TEZ/VX-561 TC
    Arm description
    Subjects received VX-659/TEZ/VX-561 TC for 4 weeks in the TC treatment period.
    Arm type
    Experimental

    Investigational medicinal product name
    VX-659
    Investigational medicinal product code
    VX-659
    Other name
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received VX-659 once daily.

    Investigational medicinal product name
    TEZ
    Investigational medicinal product code
    VX-661
    Other name
    Tezacaftor
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received TEZ once daily.

    Investigational medicinal product name
    VX-561
    Investigational medicinal product code
    VX-561
    Other name
    CTP-656
    Pharmaceutical forms
    Tablet
    Routes of administration
    Oral use
    Dosage and administration details
    Subjects received VX-561 once daily.

    Number of subjects in period 1 [1]
    Part 1: Placebo Part 1: VX-659/TEZ/IVA TC - Low Dose Part 1: VX-659/TEZ/IVA TC - Medium Dose Part 1: VX-659/TEZ/IVA TC - High Dose Part 2: TEZ/IVA Part 2: VX-659/TEZ/IVA TC Part 3: Placebo Part 3: VX-659/TEZ/VX-561 TC
    Started
    10
    11
    20
    22
    11
    18
    6
    19
    Completed
    10
    11
    20
    22
    11
    18
    6
    19
    Notes
    [1] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.
    Justification: There were 117 subjects dosed in the TC treatment period for all 3 parts. 7 subjects were dosed in the run-in period in part 2 but were not dosed in TC treatment period. Therefore, the total enrolled subjects are 124 where as the subjects reported in disposition and baseline are 117.

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Part 1: Placebo
    Reporting group description
    Subjects received placebo matched to VX-659/TEZ/IVA triple combination (TC) for 4 weeks in the TC treatment period.

    Reporting group title
    Part 1: VX-659/TEZ/IVA TC - Low Dose
    Reporting group description
    Subjects received VX-659/TEZ/IVA TC low dose for 4 weeks in the TC treatment period.

    Reporting group title
    Part 1: VX-659/TEZ/IVA TC - Medium Dose
    Reporting group description
    Subjects received VX-659/TEZ/IVA TC medium dose for 4 weeks in the TC treatment period.

    Reporting group title
    Part 1: VX-659/TEZ/IVA TC - High Dose
    Reporting group description
    Subjects received VX-659/TEZ/IVA TC high dose for 4 weeks in the TC treatment period.

    Reporting group title
    Part 2: TEZ/IVA
    Reporting group description
    Following run-in period of 4 weeks with TEZ/IVA, subjects received TEZ/IVA and placebo matched to VX-659 for 4 weeks in the TC treatment period.

    Reporting group title
    Part 2: VX-659/TEZ/IVA TC
    Reporting group description
    Following run-in period of 4 weeks with TEZ/IVA, subjects received VX-659/TEZ/IVA for 4 weeks in the TC treatment period.

    Reporting group title
    Part 3: Placebo
    Reporting group description
    Subjects received placebo matched to VX-659/TEZ/VX-561 TC for 4 weeks in the TC treatment period.

    Reporting group title
    Part 3: VX-659/TEZ/VX-561 TC
    Reporting group description
    Subjects received VX-659/TEZ/VX-561 TC for 4 weeks in the TC treatment period.

    Reporting group values
    Part 1: Placebo Part 1: VX-659/TEZ/IVA TC - Low Dose Part 1: VX-659/TEZ/IVA TC - Medium Dose Part 1: VX-659/TEZ/IVA TC - High Dose Part 2: TEZ/IVA Part 2: VX-659/TEZ/IVA TC Part 3: Placebo Part 3: VX-659/TEZ/VX-561 TC Total
    Number of subjects
    10 11 20 22 11 18 6 19 117
    Age categorical
    Units: Subjects
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    26.6 ± 6.0 32.0 ± 11.7 31.4 ± 9.7 27.2 ± 6.6 32.5 ± 7.5 33.4 ± 9.2 24.5 ± 5.3 32.5 ± 9.4 -
    Gender categorical
    Units: Subjects
        Female
    4 7 7 12 4 6 3 11 54
        Male
    6 4 13 10 7 12 3 8 63

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Part 1: Placebo
    Reporting group description
    Subjects received placebo matched to VX-659/TEZ/IVA triple combination (TC) for 4 weeks in the TC treatment period.

    Reporting group title
    Part 1: VX-659/TEZ/IVA TC - Low Dose
    Reporting group description
    Subjects received VX-659/TEZ/IVA TC low dose for 4 weeks in the TC treatment period.

    Reporting group title
    Part 1: VX-659/TEZ/IVA TC - Medium Dose
    Reporting group description
    Subjects received VX-659/TEZ/IVA TC medium dose for 4 weeks in the TC treatment period.

    Reporting group title
    Part 1: VX-659/TEZ/IVA TC - High Dose
    Reporting group description
    Subjects received VX-659/TEZ/IVA TC high dose for 4 weeks in the TC treatment period.

    Reporting group title
    Part 2: TEZ/IVA
    Reporting group description
    Following run-in period of 4 weeks with TEZ/IVA, subjects received TEZ/IVA and placebo matched to VX-659 for 4 weeks in the TC treatment period.

    Reporting group title
    Part 2: VX-659/TEZ/IVA TC
    Reporting group description
    Following run-in period of 4 weeks with TEZ/IVA, subjects received VX-659/TEZ/IVA for 4 weeks in the TC treatment period.

    Reporting group title
    Part 3: Placebo
    Reporting group description
    Subjects received placebo matched to VX-659/TEZ/VX-561 TC for 4 weeks in the TC treatment period.

    Reporting group title
    Part 3: VX-659/TEZ/VX-561 TC
    Reporting group description
    Subjects received VX-659/TEZ/VX-561 TC for 4 weeks in the TC treatment period.

    Primary: Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Close Top of page
    End point title
    Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs) [1]
    End point description
    The number of subjects analysed included only subjects who received at least one dose of study drug in the TC treatment period.
    End point type
    Primary
    End point timeframe
    From first dose of study drug in TC treatment period up to 28 days after last dose of study drug
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: Only descriptive statistics were planned. No statistical comparisons were planned for primary safety endpoint.
    End point values
    Part 1: Placebo Part 1: VX-659/TEZ/IVA TC - Low Dose Part 1: VX-659/TEZ/IVA TC - Medium Dose Part 1: VX-659/TEZ/IVA TC - High Dose Part 2: TEZ/IVA Part 2: VX-659/TEZ/IVA TC Part 3: Placebo Part 3: VX-659/TEZ/VX-561 TC
    Number of subjects analysed
    10
    11
    20
    22
    11
    18
    6
    19
    Units: Subjects
        Subjects with AEs
    9
    10
    15
    17
    9
    15
    6
    18
        Subjects with SAEs
    3
    1
    4
    1
    2
    1
    3
    2
    No statistical analyses for this end point

    Primary: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

    Close Top of page
    End point title
    Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) [2]
    End point description
    The number of subjects analysed included all randomized subjects who carry the intended CFTR allele mutation and received at least 1 dose of study drug in the TC treatment period.
    End point type
    Primary
    End point timeframe
    From Baseline through Day 29
    Notes
    [2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The study is not designed to perform between treatment group comparisons.
    End point values
    Part 1: Placebo Part 1: VX-659/TEZ/IVA TC - Low Dose Part 1: VX-659/TEZ/IVA TC - Medium Dose Part 1: VX-659/TEZ/IVA TC - High Dose Part 2: TEZ/IVA Part 2: VX-659/TEZ/IVA TC Part 3: Placebo Part 3: VX-659/TEZ/VX-561 TC
    Number of subjects analysed
    10
    11
    20
    22
    11
    18
    6
    19
    Units: Percentage points
        least squares mean (standard error)
    0.4 ± 2.8
    10.2 ± 2.7
    12.0 ± 2.0
    13.3 ± 1.9
    0.0 ± 1.9
    9.7 ± 1.5
    -5.0 ± 3.4
    12.2 ± 1.9
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From first dose of study drug in TC treatment period up to 28 days after last dose of study drug
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    20.1
    Reporting groups
    Reporting group title
    Part 1: Placebo
    Reporting group description
    Subjects received placebo matched to VX-659/TEZ/IVA TC for 4 weeks in the TC treatment period.

    Reporting group title
    Part 1: VX-659/TEZ/IVA TC - Low Dose
    Reporting group description
    Subjects received VX-659/TEZ/IVA TC low dose for 4 weeks in the TC treatment period.

    Reporting group title
    Part 1: VX-659/TEZ/IVA TC - Medium Dose
    Reporting group description
    Subjects received VX-659/TEZ/IVA TC medium dose for 4 weeks in the TC treatment period.

    Reporting group title
    Part 1: VX-659/TEZ/IVA TC - High Dose
    Reporting group description
    Subjects received VX-659/TEZ/IVA TC high dose for 4 weeks in the TC treatment period.

    Reporting group title
    Part 2: TEZ/IVA
    Reporting group description
    Following run-in period of 4 weeks with TEZ/IVA, subjects received TEZ/IVA and placebo matched to VX-659 for 4 weeks in the TC treatment period.

    Reporting group title
    Part 2: VX-659/TEZ/IVA TC
    Reporting group description
    Following run-in period of 4 weeks with TEZ/IVA, subjects received VX-659/TEZ/IVA for 4 weeks in the TC treatment period.

    Reporting group title
    Part 3: Placebo
    Reporting group description
    Subjects received placebo matched VX-659/TEZ/VX-561 TC for 4 weeks in the TC treatment period.

    Reporting group title
    Part 3: VX-659/TEZ/VX-561 TC
    Reporting group description
    Subjects received VX-659/TEZ/VX-561 TC for 4 weeks in the TC treatment period.

    Serious adverse events
    Part 1: Placebo Part 1: VX-659/TEZ/IVA TC - Low Dose Part 1: VX-659/TEZ/IVA TC - Medium Dose Part 1: VX-659/TEZ/IVA TC - High Dose Part 2: TEZ/IVA Part 2: VX-659/TEZ/IVA TC Part 3: Placebo Part 3: VX-659/TEZ/VX-561 TC
    Total subjects affected by serious adverse events
         subjects affected / exposed
    3 / 10 (30.00%)
    1 / 11 (9.09%)
    4 / 20 (20.00%)
    1 / 22 (4.55%)
    2 / 11 (18.18%)
    1 / 18 (5.56%)
    3 / 6 (50.00%)
    2 / 19 (10.53%)
         number of deaths (all causes)
    0
    0
    0
    0
    0
    0
    0
    0
         number of deaths resulting from adverse events
    Investigations
    Pulmonary function test decreased
         subjects affected / exposed
    1 / 10 (10.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory, thoracic and mediastinal disorders
    Dyspnoea
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pleuritic pain
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Infective pulmonary exacerbation of cystic fibrosis
         subjects affected / exposed
    2 / 10 (20.00%)
    1 / 11 (9.09%)
    2 / 20 (10.00%)
    1 / 22 (4.55%)
    2 / 11 (18.18%)
    1 / 18 (5.56%)
    3 / 6 (50.00%)
    1 / 19 (5.26%)
         occurrences causally related to treatment / all
    0 / 2
    0 / 1
    0 / 2
    0 / 1
    0 / 2
    0 / 1
    0 / 3
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Influenza
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    1 / 20 (5.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Respiratory tract infection viral
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    1 / 20 (5.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 1
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Pneumonia
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 5%
    Non-serious adverse events
    Part 1: Placebo Part 1: VX-659/TEZ/IVA TC - Low Dose Part 1: VX-659/TEZ/IVA TC - Medium Dose Part 1: VX-659/TEZ/IVA TC - High Dose Part 2: TEZ/IVA Part 2: VX-659/TEZ/IVA TC Part 3: Placebo Part 3: VX-659/TEZ/VX-561 TC
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    8 / 10 (80.00%)
    10 / 11 (90.91%)
    15 / 20 (75.00%)
    17 / 22 (77.27%)
    8 / 11 (72.73%)
    15 / 18 (83.33%)
    5 / 6 (83.33%)
    18 / 19 (94.74%)
    Vascular disorders
    Hot flush
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    1 / 20 (5.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Fibroadenoma of breast
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Immune system disorders
    Drug hypersensitivity
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    General disorders and administration site conditions
    Pyrexia
         subjects affected / exposed
    1 / 10 (10.00%)
    1 / 11 (9.09%)
    1 / 20 (5.00%)
    1 / 22 (4.55%)
    1 / 11 (9.09%)
    2 / 18 (11.11%)
    0 / 6 (0.00%)
    3 / 19 (15.79%)
         occurrences all number
    1
    1
    1
    1
    1
    2
    0
    3
    Fatigue
         subjects affected / exposed
    0 / 10 (0.00%)
    2 / 11 (18.18%)
    2 / 20 (10.00%)
    0 / 22 (0.00%)
    1 / 11 (9.09%)
    0 / 18 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
         occurrences all number
    0
    2
    2
    0
    1
    0
    1
    0
    Pain
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    1 / 22 (4.55%)
    1 / 11 (9.09%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    2 / 19 (10.53%)
         occurrences all number
    0
    0
    0
    1
    1
    0
    0
    2
    Application site rash
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Asthenia
         subjects affected / exposed
    1 / 10 (10.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Exercise tolerance decreased
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    Influenza like illness
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    1 / 20 (5.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    Psychiatric disorders
    Irritability
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    1 / 20 (5.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    Reproductive system and breast disorders
    Testicular pain
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Vaginal discharge
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 11 (9.09%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Vaginal haemorrhage
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Injury, poisoning and procedural complications
    Laceration
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Wound
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Investigations
    Blood creatine phosphokinase increased
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 11 (9.09%)
    1 / 20 (5.00%)
    3 / 22 (13.64%)
    2 / 11 (18.18%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    1
    1
    3
    3
    1
    0
    0
    Neutrophil count increased
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    4
    2
    0
    Aspartate aminotransferase increased
         subjects affected / exposed
    1 / 10 (10.00%)
    1 / 11 (9.09%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    1 / 11 (9.09%)
    1 / 18 (5.56%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
         occurrences all number
    1
    1
    0
    0
    1
    1
    1
    0
    Bacterial test positive
         subjects affected / exposed
    1 / 10 (10.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    1
    0
    0
    0
    0
    1
    0
    1
    Blood glucose increased
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    1 / 11 (9.09%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    2
    0
    0
    International normalised ratio increased
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    1 / 22 (4.55%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    0
    1
    Lymphocyte count decreased
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    2
    1
    0
    Prothrombin time prolonged
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    1 / 22 (4.55%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    0
    1
    Weight increased
         subjects affected / exposed
    1 / 10 (10.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    1 / 22 (4.55%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    0
    1
    0
    1
    0
    0
    Activated partial thromboplastin time prolonged
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    1 / 22 (4.55%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    1
    Alanine aminotransferase increased
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 11 (9.09%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    1
    0
    0
    Blood glucose decreased
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    1 / 22 (4.55%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    1
    0
    Blood triglycerides increased
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    1 / 11 (9.09%)
    0 / 18 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    1
    0
    Pulmonary function test decreased
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    1
    Blood alkaline phosphatase increased
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Blood chloride decreased
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    Blood creatinine decreased
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Blood glucose fluctuation
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Blood lactate dehydrogenase increased
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    1 / 11 (9.09%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    Blood potassium increased
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    1 / 11 (9.09%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    Blood sodium decreased
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    Body temperature increased
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 11 (9.09%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Coronavirus test positive
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    1 / 11 (9.09%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    Crystal urine present
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Forced expiratory volume decreased
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    1 / 11 (9.09%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    Glucose urine present
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Haemoglobin decreased
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 11 (9.09%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    0
    0
    Monocyte count increased
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    Red blood cells urine positive
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Urinary sediment present
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Weight decreased
         subjects affected / exposed
    1 / 10 (10.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    White blood cell count increased
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    Respiratory, thoracic and mediastinal disorders
    Cough
         subjects affected / exposed
    1 / 10 (10.00%)
    3 / 11 (27.27%)
    6 / 20 (30.00%)
    4 / 22 (18.18%)
    2 / 11 (18.18%)
    4 / 18 (22.22%)
    2 / 6 (33.33%)
    4 / 19 (21.05%)
         occurrences all number
    1
    3
    6
    5
    2
    4
    2
    5
    Sputum increased
         subjects affected / exposed
    0 / 10 (0.00%)
    2 / 11 (18.18%)
    1 / 20 (5.00%)
    3 / 22 (13.64%)
    1 / 11 (9.09%)
    3 / 18 (16.67%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    2
    1
    4
    2
    3
    0
    1
    Oropharyngeal pain
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    3 / 20 (15.00%)
    4 / 22 (18.18%)
    0 / 11 (0.00%)
    2 / 18 (11.11%)
    0 / 6 (0.00%)
    2 / 19 (10.53%)
         occurrences all number
    0
    0
    3
    4
    0
    2
    0
    2
    Haemoptysis
         subjects affected / exposed
    0 / 10 (0.00%)
    2 / 11 (18.18%)
    1 / 20 (5.00%)
    0 / 22 (0.00%)
    1 / 11 (9.09%)
    1 / 18 (5.56%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
         occurrences all number
    0
    2
    1
    0
    1
    1
    1
    0
    Respiration abnormal
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 11 (9.09%)
    1 / 20 (5.00%)
    3 / 22 (13.64%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    2
    1
    3
    0
    0
    0
    0
    Nasal congestion
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    1 / 20 (5.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    4 / 18 (22.22%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    4
    0
    0
    Sinus congestion
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    2 / 22 (9.09%)
    1 / 11 (9.09%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    2 / 19 (10.53%)
         occurrences all number
    0
    0
    0
    2
    1
    0
    0
    2
    Dyspnoea
         subjects affected / exposed
    1 / 10 (10.00%)
    1 / 11 (9.09%)
    1 / 20 (5.00%)
    0 / 22 (0.00%)
    1 / 11 (9.09%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    1
    1
    1
    0
    1
    0
    0
    0
    Lower respiratory tract congestion
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    1 / 11 (9.09%)
    2 / 18 (11.11%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    1
    2
    0
    1
    Productive cough
         subjects affected / exposed
    0 / 10 (0.00%)
    2 / 11 (18.18%)
    1 / 20 (5.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    2
    1
    0
    0
    1
    0
    0
    Wheezing
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    3 / 20 (15.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    3
    0
    0
    0
    0
    0
    Paranasal sinus discomfort
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 11 (9.09%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    1
    0
    0
    Rales
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    2 / 6 (33.33%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    2
    0
    Rhinorrhoea
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    2
    0
    0
    Sinus pain
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    2 / 22 (9.09%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    2
    0
    0
    0
    0
    Sputum discoloured
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    1 / 20 (5.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    2
    0
    0
    0
    0
    0
    Bronchospasm
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Epistaxis
         subjects affected / exposed
    1 / 10 (10.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Nasal discharge discolouration
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    1 / 20 (5.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    Throat irritation
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Throat tightness
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Blood and lymphatic system disorders
    Lymphopenia
         subjects affected / exposed
    1 / 10 (10.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Nervous system disorders
    Headache
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 11 (9.09%)
    4 / 20 (20.00%)
    4 / 22 (18.18%)
    0 / 11 (0.00%)
    3 / 18 (16.67%)
    1 / 6 (16.67%)
    1 / 19 (5.26%)
         occurrences all number
    0
    1
    4
    4
    0
    3
    1
    1
    Dizziness
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    2
    Lethargy
         subjects affected / exposed
    1 / 10 (10.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Migraine
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Sinus headache
         subjects affected / exposed
    1 / 10 (10.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0
    Syncope
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Ear and labyrinth disorders
    Vertigo
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    1 / 20 (5.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    2
    Ear congestion
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Motion sickness
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Gastrointestinal disorders
    Nausea
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    3 / 22 (13.64%)
    2 / 11 (18.18%)
    2 / 18 (11.11%)
    0 / 6 (0.00%)
    2 / 19 (10.53%)
         occurrences all number
    0
    0
    0
    3
    2
    2
    0
    2
    Vomiting
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    1 / 22 (4.55%)
    2 / 11 (18.18%)
    2 / 18 (11.11%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    1
    2
    2
    0
    2
    Constipation
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    1 / 20 (5.00%)
    3 / 22 (13.64%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    1
    3
    0
    0
    0
    1
    Diarrhoea
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 11 (9.09%)
    0 / 20 (0.00%)
    1 / 22 (4.55%)
    0 / 11 (0.00%)
    2 / 18 (11.11%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    1
    0
    1
    0
    2
    0
    1
    Abdominal pain
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 11 (9.09%)
    1 / 20 (5.00%)
    0 / 22 (0.00%)
    1 / 11 (9.09%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    1
    1
    0
    1
    1
    0
    0
    Abdominal pain upper
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    2 / 18 (11.11%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    2
    0
    0
    Flatulence
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    1 / 22 (4.55%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    1
    0
    0
    0
    1
    Faeces discoloured
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    1 / 20 (5.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    Food poisoning
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    1 / 11 (9.09%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    Gastrooesophageal reflux disease
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    1 / 20 (5.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    Pancreatic failure
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    1 / 11 (9.09%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    Parotid gland enlargement
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Salivary hypersecretion
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    1 / 20 (5.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    Toothache
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    1 / 20 (5.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    Renal and urinary disorders
    Micturition urgency
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    1 / 20 (5.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    Skin and subcutaneous tissue disorders
    Rash
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    1 / 22 (4.55%)
    0 / 11 (0.00%)
    2 / 18 (11.11%)
    0 / 6 (0.00%)
    2 / 19 (10.53%)
         occurrences all number
    0
    0
    0
    1
    0
    2
    0
    2
    Acne
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    1
    Dermatitis
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    1 / 11 (9.09%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    Rash erythematous
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    1 / 20 (5.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    1
    0
    0
    0
    0
    0
    Skin disorder
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Musculoskeletal and connective tissue disorders
    Back pain
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    1 / 20 (5.00%)
    0 / 22 (0.00%)
    1 / 11 (9.09%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    1
    0
    1
    1
    0
    0
    Flank pain
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Intervertebral disc protrusion
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    1
    0
    Musculoskeletal pain
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Metabolism and nutrition disorders
    Vitamin D deficiency
         subjects affected / exposed
    0 / 10 (0.00%)
    1 / 11 (9.09%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    1 / 6 (16.67%)
    0 / 19 (0.00%)
         occurrences all number
    0
    1
    0
    0
    0
    0
    1
    0
    Abnormal loss of weight
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Decreased appetite
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Hypophosphataemia
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Increased appetite
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Infections and infestations
    Infective pulmonary exacerbation of cystic fibrosis
         subjects affected / exposed
    1 / 10 (10.00%)
    2 / 11 (18.18%)
    1 / 20 (5.00%)
    3 / 22 (13.64%)
    1 / 11 (9.09%)
    4 / 18 (22.22%)
    0 / 6 (0.00%)
    2 / 19 (10.53%)
         occurrences all number
    1
    2
    1
    3
    1
    4
    0
    2
    Nasopharyngitis
         subjects affected / exposed
    1 / 10 (10.00%)
    2 / 11 (18.18%)
    1 / 20 (5.00%)
    3 / 22 (13.64%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    1
    2
    2
    3
    0
    0
    0
    1
    Upper respiratory tract infection
         subjects affected / exposed
    1 / 10 (10.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    2 / 22 (9.09%)
    0 / 11 (0.00%)
    2 / 18 (11.11%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    0
    2
    0
    2
    0
    0
    Sinusitis
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    1 / 22 (4.55%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    1
    0
    1
    0
    1
    Influenza
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    2 / 19 (10.53%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    2
    Cellulitis
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Chronic sinusitis
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    1 / 11 (9.09%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    1
    0
    0
    0
    Genital infection fungal
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Lower respiratory tract infection
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Oral candidiasis
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Respiratory tract infection viral
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    1 / 18 (5.56%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    0
    0
    0
    0
    0
    1
    0
    0
    Viral upper respiratory tract infection
         subjects affected / exposed
    0 / 10 (0.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    1 / 19 (5.26%)
         occurrences all number
    0
    0
    0
    0
    0
    0
    0
    1
    Vulvovaginal mycotic infection
         subjects affected / exposed
    1 / 10 (10.00%)
    0 / 11 (0.00%)
    0 / 20 (0.00%)
    0 / 22 (0.00%)
    0 / 11 (0.00%)
    0 / 18 (0.00%)
    0 / 6 (0.00%)
    0 / 19 (0.00%)
         occurrences all number
    1
    0
    0
    0
    0
    0
    0
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    30 Jun 2017
    Added study drug doses, revised elements of the study design including treatment arms, sample size, and study duration, and revised inclusion/exclusion criteria.
    01 Sep 2017
    Added Part 3 to evaluate VX-659 in triple combination with TEZ/VX-561.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None reported
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA